Consistent with these findings, patients with PDGFRA-positive myeloid neoplasm, one of the most aggressive forms of HES, have higher AECs than patients with other clinical subtypes of HES and dramatic resolution of clinical manifestations following normalization of the AEC with imatinib therapy (10). Here, PDGFRA is linked to myeloid neoplasm.